[1]
Barro, C., Affonso, A.A.M., Waquar, A., Aragao, N., Bakheet, A., Cajiao, K., Souza, A.B.C., Díaz, L.A.Q., Fowler, C.M., Herrera, R., Huapaya, L.A.N., Kornienko, K., Magalhães, A.M.V., Menezes, T. d. O., Mordojovich, M.-A., Nosé, R., Pan, H., Persivale, K.S., Poveda, C., Ramos, C., Rodrigues, M.A., Ruiz, J.M.V., Soares, R. and DangHan, X. 2018. The INCA trial: a multicenter, randomized, phase II, open-label clinical trial to evaluate the combination therapy with Ipilimumab plus Nivolumab versus Chemotherapy (Pemetrexate-Cisplatin) in patients with Advanced non-squamous NSCLC naive to treatment. Principles and Practice of Clinical Research. 4, 1 (Jul. 2018), 6-13.